Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 19;397(10292):2331-2333.
doi: 10.1016/S0140-6736(21)01290-3. Epub 2021 Jun 3.

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C Wall  1 , Mary Wu  2 , Ruth Harvey  2 , Gavin Kelly  2 , Scott Warchal  2 , Chelsea Sawyer  2 , Rodney Daniels  2 , Philip Hobson  2 , Emine Hatipoglu  3 , Yenting Ngai  3 , Saira Hussain  2 , Jerome Nicod  2 , Robert Goldstone  2 , Karen Ambrose  2 , Steve Hindmarsh  2 , Rupert Beale  1 , Andrew Riddell  2 , Steve Gamblin  2 , Michael Howell  2 , George Kassiotis  4 , Vincenzo Libri  5 , Bryan Williams  5 , Charles Swanton  2 , Sonia Gandhi  6 , David Lv Bauer  7
Affiliations

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C Wall et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CSw reports grants from BMS, Ono-Pharmaceuticals, Boehringer-Ingelheim, Roche-Ventana, Pfizer and Archer Dx, unrelated to this Correspondence; personal fees from Genentech, Sarah Canon Research Institute, Medicxi, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, BMS, Illumina, GlaxoSmithKline, MSD, and Roche-Ventana, unrelated to this Correspondence; and stock options from Apogen Biotech, Epic Biosciences, GRAIL, and Achilles Therapeutics, unrelated to this Correspondence. All other authors declare no competing interests. ECW, MW, SG, and DLVB contributed equally. GKa, CSw, SGan, and DLVB are joint senior authors. RB and DLVB are members of the Genotype-to-Phenotype UK National Virology Consortium. Funding details and acknowledgments can be found in the appendix. All data (anonymised) and full R code to produce all figures and statistical analysis presented in this Correspondence are available online on Github.

References

    1. Public Health England SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 13. May 27, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
    1. Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Feb 4, 2021. https://virological.org/t/preliminary-genomic-characterisation-of-an-eme...
    1. Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021 doi: 10.1038/s41586-021-03647-4. published online May 24. - DOI - PubMed
    1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 doi: 10.1038/s41591-021-01377-8. published online May 17. - DOI - PubMed
    1. Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. KHub. 2021 doi: 10.1101/2021.05.22.21257658. published online May 24. (preprint). - DOI - PubMed

Publication types

LinkOut - more resources